Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastat
Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.